Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL11707806 | 0.89 | CA1 (0.56) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL11317378 | 0.88 | CA1 (0.56) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL1649527 | 0.88 | CA1 (0.79) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL11529139 | 0.86 | CA1 (0.76) | CA1CA2KMT2AHTTALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8646817 | 0.86 | CA1 (0.76) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL11063854 | 0.84 | CA1 (0.58) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL28328289 | 0.84 | CA1 (0.54) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL1509253 | 0.83 | CA1 (0.56) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL8633874 | 0.81 | CA1 (1.00) | CA1CA2KMT2AHTTALDH1A1 | |
| SCHEMBL4850974 | 0.81 | CA1 (0.54) | CA1CA2KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258315-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | XAVIER UNIVERSITY OF LOUISIANA (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240158351-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2024-05-16 | — | — | US | disclosed |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | XAVIER UNIVERSITY OF LOUISIANA (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | XAVIER UNIVERSITY OF LOUISIANA | 2021-10-21 | — | — | US | disclosed |
| US-4480105-A | PHOTOCROSSLINKING POLYMERS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4385182-A | SENSITIZERS OR PHOTOINITIATORS | CIBA-GEIGY CORPORATION (US) | 1983-05-24 | — | — | US | disclosed |
| US-4363917-A | SENSITIZERS FOR PHOTOCROSSLINKABLE POLYMERS; PHOTOPOLYMERIZATION INITIATORS | CIBA-GEIGY CORPORATION (US) | 1982-12-14 | — | — | US | disclosed |
| US-4233220-A | Imidyl-benzene-dicarboxylic and -tricarboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4132716-A | Imidyl-benzene-dicarboxylic and -tricarboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1979-01-02 | — | — | US | disclosed |
| US-4007201-A | ANTIDIABETIC | KYORIN PHARMACEUTICAL CO. LTD. (JA) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258315-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | RPS6KA6, RPS6KA1, RPS6KA3 | CA1 4839/4885CA2 4437/4885KMT2A 2003/4885 |
| US-20210323919-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | CA1 4839/4885CA2 4437/4885KMT2A 2003/4885 |
| US-11912660-B2 | S6K1 protein kinase inhibitors as cancer therapeutics | RPS6KA6, RPS6KA1, RPS6KA3 | CA1 4839/4885CA2 4437/4885KMT2A 2003/4885 |
| US-20240158351-A1 | S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS | RPS6KA6, RPS6KA1, RPS6KA3 | CA1 4839/4885CA2 4437/4885KMT2A 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.